NEW YORK-The American Society of Breast Disease (ASBD) began in 1976 as a relatively small group of physicians interested in studying diseases of the breast. It soon expanded into a multi-disciplinary organization whose stated mission is “to provide a forum for learning and sharing new developments related to breast disease.” The operative word for this group is “multidisciplinary.”
Computer-aided diagnosis (CAD) can help radiologists find early-stage breast cancers that might otherwise be missed, according to findings from a retrospective study presented at the “Era of Hope” Department of Defense Breast Cancer Research Program meeting.
BETHESDA, Md-Speakers at the National Institutes of Health Consensus Development Conference on Adjuvant Therapy for Breast Cancer will address the data on adjuvant chemotherapy, hormonal therapy, and other aspects of postsurgical treatment. The 2½-day meeting convenes on Nov. 1.
ATLANTA-All breast cancer patients under age 35 should be offered adjuvant chemotherapy even if they have low-risk disease, Mads Melbye, MD, PhD, said at the Era of Hope: U.S. Department of Defense Breast Cancer Research Program Meeting.
Three studies presented at the “Era of Hope” Department of Defense Breast Cancer Research Program meeting described ways in which the body’s own genes and immune system are being used to guide and develop promising new therapeutic approaches.
ATLANTA-Experimental use of laser therapy to destroy small, localized breast tumors is showing promise as an alternative to lumpectomy in highly selected patients, researchers from England and the United States reported at the Era of Hope: U.S. Department of Defense Breast Cancer Research Program Meeting.
ATLANTA-Susan M. Love, MD, predicts that significant new information about breast cancer will emerge as doctors begin using a new duct cell screening technique. Dr. Love discussed her work on ductal lavage at the Era of Hope: U.S. Department of Defense Breast Cancer Research Program Meeting in Atlanta, and updated results of a study of the technique were presented at the Second Annual Lynn Sage Breast Cancer Symposium in Chicago.
ATLANTA-An immunogenic marker, TA-90, can detect breast cancers missed by mammograms and other known markers, Rishab K. Gupta, PhD, said at the Era of Hope: U.S. Department of Defense Breast Cancer Research Program Meeting.
Two studies presented at the “Era of Hope” Department of Defense Breast Cancer Research Program meeting exemplify different but equally promising approaches to the development of cancer vaccines.
WASHINGTON-More than 2.5 million mammograms and Papanicolaou tests were provided to women in the first 9 years of the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), managed by the Centers for Disease Control and Prevention (CDC). The total includes 1,157,207 mammograms and 1,353,684 Pap tests administered from 1991 through September 1999.
I was surprised to find inaccurate information in the July 2000 issue of Oncology News International, in an article on page 4, “NCI Urges Support of Ongoing Breast Cancer Transplant Trial.”
Taxanes are the most active drugs in the treatment of metastatic breast and ovarian cancer. Weekly therapy with paclitaxel produces notable activity, with remarkably low toxicity.
This phase I study was undertaken to define the maximum tolerated dose, the dose-limiting toxicity, and the recommended dose of UFT plus leucovorin and vinorelbine in combination treatment of patients with metastatic breast cancer previously treated with one chemotherapy regimen. The pharmacokinetics of UFT and vinorelbine were also evaluated.
This article describes the design and early results of an open-label, nonrandomized phase I/II trial of oral UFT plus leucovorin therapy in combination with bolus injections of epirubicin and cyclophosphamide in patients with advanced or metastatic breast cancer. This study was designed as a cohort dose-escalation study with the principal aims being to determine dose-limiting toxicity, overall toxicity, maximum tolerated dose, tumor response, and time to disease progression.
CANTON, Ohio-Neoadjuvant breast cancer therapy research has revealed that “epirubicin has good activity in the neoadjuvant setting and was associated with prolonged survival in four studies, although this remains to be confirmed,” Terry Mamounas, MD, stated. Dr. Mamounas, Medical Director at Aultman Memorial Hospital in Canton, Ohio, spoke at the clinical investigators’ workshop sponsored by the University of Texas M. D. Anderson Cancer Center and Pharmacia Oncology.
NEW YORK-“The number one question that I used to get as a clinician taking care of people with breast cancer and people worried about breast cancer was about hormone replacement therapy. Now, by far, the number one question is about soybeans,” said Larry Norton, MD, chief of Breast Medicine and head of the Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center.
MUNICH, Germany-‘‘Epirubicin-containing regimens significantly prolong relapse-free and overall survival rates compared with standard regimens” for treating breast cancer, Michael Untch, MD, reported at a clinical investigators’ workshop. ‘‘The dose-response relationship for epirubicin,” he continued, “translated into significant improvements in outcome, and dose-intensification of epirubicin and paclitaxel was well tolerated.”
ROCHESTER, Minnesota-Researchers have begun to suspect that estrogen might be important not only for its receptor-mediated effects but also because it may exert genotoxic effects, reported James N. Ingle, MD. “There is evidence that estrogen genotoxicity may play a role in breast cancer development. That is, in the course of metabolism of estrogen, semi-quinones and quinones are formed, which can result in depurinating DNA adducts,” Dr. Ingle stated.
WASHINGTON-Stanford University researchers have developed a device for gene comparison that could lead to a more exact way to categorize cancer tumors and assess the survival chances of patients. In initial experiments with breast cancer patients, they detected specific gene combinations in tumors and found that certain combinations indicated either a good or bad prognosis.
PISA, Italy-‘‘Anthracycline/taxane combinations given upfront should be the new standard of care for metastatic breast cancer,” Pierfranco Conte, MD, said at a clinical investigators’ workshop sponsored by the University of Texas M. D. Anderson Cancer Center and Pharmacia Oncology. Dr. Conte is chief of the Division of Medical Oncology at St. Chiara Hospital in Pisa, Italy.
TORONTO-Epirubicin (Ellence) and doxorubicin (Adriamycin) in combination regimens for adjuvant treatment of breast cancer will be compared in a major randomized controlled trial sponsored by the National Cancer Institute of Canada (NCIC), according to Maureen Trudeau, MD, head of systemic therapy at Sunnybrook Regional Cancer Centre in Toronto, Ontario. Dr. Trudeau described the reasoning behind and the design of NCIC CTG-MA.21 at a clinical investigators’ workshop sponsored by the University of Texas M. D. Anderson Cancer Center and Pharmacia Oncology.
NEW ORLEANS-Premenopausal women with breast cancer who receive goserelin (Zoladex) have an increased event-free survival over 5 years, regardless of whether they also receive tamoxifen (Nolvadex) or have had prior chemotherapy. This key finding from 5-year follow-up of the Zoladex in Premenopausal Patients (ZIPP) trial was presented at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Initial data from a phase II study of exemestane (Aromasin) as first-line treatment of advanced breast cancer in postmenopausal women suggest that the new agent may extend the time that patients remain free of tumor growth compared to tamoxifen (Nolvadex).
ATLANTA-In a retrospective review of more than 12,000 screening mammograms, computer technology found 52% of missed cancers, Kunio Doi, PhD, reported at the Era of Hope meeting, featuring research sponsored by the US Department of Defense Breast Cancer Research Program.
PISA, ITALY-Gemcitabine, epirubicin, and paclitaxel (GET) is a highly active regimen in previously treated metastatic breast cancer, Pierfranco Conte, MD, reported at a clinical investigators’ workshop sponsored by the University of Texas M. D. Anderson Cancer Center and Pharmacia Oncology. Dr. Conte is Chief of the Division of Medical Oncology at St. Chiara Hospital in Pisa, Italy.
